Endometriosis: the ultimate hormonal disease.

  title={Endometriosis: the ultimate hormonal disease.},
  author={Bilgin Gurates and Serdar E. Bulun},
  journal={Seminars in reproductive medicine},
  volume={21 2},
  • B. Gurates, S. Bulun
  • Published 1 May 2003
  • Biology, Medicine
  • Seminars in reproductive medicine
Estrogen is an extremely potent mitogen for endometrium and endometriosis. Progesterone, on the other hand, inhibits the mitogenic action of estrogen on endometrium and enhances differentiation. These antiproliferative and differentiative effects of progesterone are less pronounced on endometriosis tissue compared with endometrium. Thus, endometriosis is, at least in part, resistant to progesterone action. The product of a single gene named aromatase synthesizes estrogen. The potent estrogen… 
Selective Estrogen-Receptor Modulators and Aromatase Inhibitors: Promising New Medical Therapies for Endometriosis?
At present, it is too early to conclude that aromatase inhibitors, COX-2 inhibitors or selective estrogen-receptor modulators really present any added value compared with the existing drugs that can be used to achieve hormonal suppression in the medical treatment of endometriosis.
Immune-endocrine interactions in endometriosis.
Better understanding of immune-endocrine interactions will set the stage for effective immune-targeted therapies not only for endometriosis but also for other endometrial diseases such as adenomyosis, recurrent reproductive failure and implantation-related infertility.
Aromatase inhibitors and cyclooxygenase-2 (COX-2) inhibitors in endometriosis: new questions--old answers?
The Role of Endometrium in Endometriosis
Experimental Murine Endometriosis Induces DNA Methylation and Altered Gene Expression in Eutopic Endometrium1
It is demonstrated that normal endometrium, when placed in an ectopic location to create experimental endometriosis, led to characteristic changes in gene expression in eutopic endometricrium, suggesting the existence of a signal conduction pathway from endometRIosis that alters endometrial gene expression through altered Pgr signaling and epigenetic programming.
Aberrant DNA methylation status of endometriosis: Epigenetics as the pathogenesis, biomarker and therapeutic target
This review summarizes the recent studies on the aberrant DNA methylation status and aberrant expression of DNA methyltransferases, which regulateDNA methylation, in endometriosis and discusses the recent information on the diagnostic and therapeutic implications of epigenetic alterations occurring in endometricriosis.
Markers of Local and Systemic Estrogen Metabolism in Endometriosis
Eutopic endometrium of women with endometriosis metabolizes estrogen preferentially to the biologically active 2OHE2, and potentially genotoxic 4OHE1 and 4 OHE2 metabolites, which contributes to further understanding of endometRIosis etiology, its link to ovarian cancer, and could help identifying an endometrial biomarker of the disease.
Advances in the management of endometriosis: an update for clinicians.
Management of endometriosis focuses on pain relief and includes medical and surgical treatment, and newer options for treatment include depot medroxyprogesterone acetate subcutaneous injection, as well as several agents under investigation that may prove to have therapeutic potential.